Scynexis (SCYX) Free Cash Flow Growth (3y) (2016 - 2026)
Scynexis (SCYX) Free Cash Flow Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 14.41% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 216.31% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 4.08% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 49.44% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -10.40% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -9.38% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 134.18% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Scynexis | 60.54 Mn | -54.16 Mn | - | -30.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30.06% |
| Mar 31, 2026 | 24.63% |
| Dec 31, 2025 | 41.06% |
| Sep 30, 2025 | 27.09% |
| Jun 30, 2025 | 26.11% |
| Mar 31, 2025 | 22.42% |
| Dec 31, 2024 | 26.59% |
| Sep 30, 2024 | 26.94% |
| Jun 30, 2024 | 2.83% |
| Mar 31, 2024 | -62.32% |
| Dec 31, 2023 | 22.42% |
| Sep 30, 2023 | 48.24% |
| Jun 30, 2023 | 118.28% |
| Mar 31, 2023 | -10.42% |
| Dec 31, 2022 | -19.22% |
| Sep 30, 2022 | -29.34% |
| Jun 30, 2022 | -33.79% |
| Mar 31, 2022 | -34.98% |
| Dec 31, 2021 | -59.72% |
| Sep 30, 2021 | -39.36% |